首页> 外国专利> Short chain chlorinated paraffins FC day combined with growth factor has high affinity, tolerance and specificity

Short chain chlorinated paraffins FC day combined with growth factor has high affinity, tolerance and specificity

机译:短链氯化石蜡FC天结合生长因子具有高亲和力,耐受性和特异性

摘要

1. Property 1: the insulating binding protein binding TGFB1, wherein the binding protein includes the first polypeptide chain and the second polypeptide chain, both of which have the first and second polypeptide chains, From n-final to c-final (domain name VH) (enlaczador 1) (enlaczador VL) - (enlaczador 2) (enlaczador 2) (bisagra) 8346; - (Fc region) VH domain name includes a main variable heavy complementary region (HCDR1),A critical complementary region of heavy variable 2 (HCDR2) and a critical complementary region of heavy variable 3 (HCDR3),6. Considering that HCB 1 is the amino acid sequence of CAS No. 22, CAS No. 23 is the amino acid sequence of CAS No. 24, CAS No. 25, CAS No. 26 and CAS No. 30; In the VL domain, it includes a variable region (LCDR1) that determines light complementarity,The decision region of one light variable 2 (LCDR2) and one light variable 3 (LCDR3),Chemical Abstracts 1 has the amino acid sequence of Chemical Abstracts 27; Chemical Abstracts 2 has the amino acid sequence of Chemical Abstracts 28; Chemical Abstracts 3 has the amino acid sequence of Chemical Abstracts 29; P is 0 or 1, n is 0 or 1, M is 0 or 1. Requirement 24: an isolated polynucleotide consisting of a nucleoside sequence that encodes binding proteins according to any one of the requirements of 1-23. 13. Claim 33: an ingredient, including any polymer protein of grades 1-23. Claim 37: claimed method 36In this case, the disease or disease is selected from a group consisting of fibrous diseases, cancer, immune system mediated diseases and a combination of these diseases.
机译:1.性质1:绝缘结合蛋白结合TGFB1,其中结合蛋白包括第一多肽链和第二多肽链,两者均具有第一多肽链和第二多肽链,从n-末端到c-末端(域名VH )(enlaczador 1)(enlaczador VL)-(enlaczador 2)(enlaczador 2)(bisagra)8346; -(Fc区)VH域名包括一个主要可变重互补区(HCDR1),一个重可变2的关键互补区(HCDR2)和一个重可变3的关键互补区(HCDR3),6。考虑到HCB 1是CAS No.22的氨基酸序列,CAS No.23是CAS No.24,CAS No.25,CAS No.26和CAS No.30的氨基酸序列。在VL域中,它包括一个决定光互补性的可变区(LCDR1),一个光变2(LCDR2)和一个光变3(LCDR3)的决定区,化学文摘1具有化学文摘的氨基酸序列27 ;化学文摘2具有化学文摘28的氨基酸序列;化学文摘3具有化学文摘29的氨基酸序列; P为0或1,n为0或1,M为0或1。要求24:由核苷序列组成的分离的多核苷酸,所述核苷序列编码根据1-23的任一项要求的结合蛋白。 13.权利要求33:一种成分,包括1-23级的任何聚合物蛋白。 37.权利要求的方法36在这种情况下,疾病选自纤维性疾病,癌症,免疫系统介导的疾病以及这些疾病的组合。

著录项

  • 公开/公告号AR103839A1

    专利类型

  • 公开/公告日2017-06-07

    原文格式PDF

  • 申请/专利权人 GENZYME CORPORATION;

    申请/专利号AR2016P100559

  • 发明设计人

    申请日2016-03-03

  • 分类号C07K16;A61K39/395;A61P35;C07K16/22;C12N15/13;C12N15/63;C12N15/85;C12P21/02;

  • 国家 AR

  • 入库时间 2022-08-21 13:40:58

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号